Creative Medical Technology Holdings (CELZ) Other Non Operating Income (2011 - 2021)
Creative Medical Technology Holdings (CELZ) posted quarterly Other Non Operating Income of $291723.0 for Q4 2019, up 430.59% year-over-year from $54981.2 in Q4 2018, and up 118.07% quarter-over-quarter from -$1.6 million in Q3 2019.
Creative Medical Technology Holdings (CELZ) Other Non Operating Income (2011 - 2021) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Other Non Operating Income for 8 consecutive years, with $291723.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Other Non Operating Income rose 430.59% year-over-year to $291723.0; the TTM figure through Sep 2020 stood at $291723.0 (up 114.16% YoY), while the FY2019 annual figure was -$366042.0, down 189.63% from the prior year.
- Other Non Operating Income improved to $291723.0 in Q4 2019 per CELZ's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $650929.0 in Q2 2018 and bottomed at -$1.6 million in Q3 2019.
- Historically, Other Non Operating Income has averaged -$128154.6 across 4 years, with a median of -$2592.5 in 2015.
- On a YoY basis, Other Non Operating Income climbed as much as 430.59% in 2019 and fell as far as 131.58% in 2019.
- Creative Medical Technology Holdings' Other Non Operating Income stood at -$2567.0 in 2015, then dropped by 1.99% to -$2618.0 in 2016, then sank by 3270.66% to -$88244.0 in 2018, then soared by 430.59% to $291723.0 in 2019.
- Business Quant data shows CELZ's Other Non Operating Income at $291723.0 in Q4 2019, -$1.6 million in Q3 2019, and -$357292.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Creative Medical Technology Holdings | 1.88 Mn | 1.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 28.48 Mn |
| Dec 31, 2020 | -37.98 Mn |
| Sep 30, 2020 | 926,532.00 |
| Jun 30, 2020 | -1.33 Mn |
| Mar 31, 2020 | 4.40 Mn |
| Dec 31, 2019 | 291,723.00 |
| Sep 30, 2019 | -1.61 Mn |
| Mar 31, 2019 | -357,292.00 |
| Dec 31, 2018 | -88,244.00 |
| Jun 30, 2018 | 650,929.00 |
| Mar 31, 2018 | -154,284.00 |
| Mar 31, 2016 | -2,618.00 |
| Sep 30, 2015 | -2,567.00 |
| Jun 30, 2015 | -2,502.00 |
| Mar 31, 2015 | -2,280.00 |
| Sep 30, 2014 | -2,200.00 |
| Jun 30, 2014 | -2,106.00 |
| Mar 31, 2013 | -1,595.00 |
| Mar 31, 2012 | -1,240.00 |
| Jun 30, 2011 | -1,025.00 |